Original language | English |
---|---|
Pages (from-to) | 733-736 |
Number of pages | 4 |
Journal | Expert Opinion on Therapeutic Targets |
Volume | 11 |
Issue number | 6 |
DOIs | |
State | Published - Jun 2007 |
Funding
Funders | Funder number |
---|---|
National Institute of Mental Health | |
Michael J. Fox Foundation for Parkinson's Research | AL-108 |
Access to Document
Other files and links
Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver
}
In: Expert Opinion on Therapeutic Targets, Vol. 11, No. 6, 06.2007, p. 733-736.
Research output: Contribution to journal › Article › peer-review
TY - JOUR
T1 - The role of vasoactive intestinal peptide in neuroprotection
T2 - Interview with Professor Illana Gozes
AU - Quigley, Emma
AU - Gozes, Illana
N1 - Funding Information: Allon Therapeutics periodically reports progress; for example, on 15th March 2007 it reported that the two formulations of NAP, the intranasal (AL-108) and the intravenous (AL-208) are currently in Phase II clinical trials. AL-108 is at present being evaluated in a Phase II efficacy trial as part of Allon’s Alzheimer’s programme in mild cognitive impairment. This trial is expected to complete enrolment at the end of 2007. It was also reported that AL-108 was recently selected by the National Institute of Mental Health funded project the Treatment Unit for Research of Neurocognition in Schizophrenia for another Phase II efficacy trial evaluating it as a treatment for schizophrenia-related cognitive impairment. Furthermore, the company received funding from The Michael J Fox Foundation for Parkinson’s Research to evaluate AL-108 in preclinical models as a potential treatment of Parkinson’s disease. The studies are under way and, if positive, Allon would be in a position to begin a Phase II clinical trial to evaluate the drug’s effectiveness in Parkinson’s disease patients as early as 2008. Allon also recently announced that AL-208 had progressed into the randomized portion of its Phase II human clinical trial evaluating it as a treatment for mild cognitive impairment that commonly occurs following coronary bypass graft surgery. This trial is expected to be completed in the second half of 2007.
PY - 2007/6
Y1 - 2007/6
UR - http://www.scopus.com/inward/record.url?scp=34250158719&partnerID=8YFLogxK
U2 - 10.1517/14728222.11.6.733
DO - 10.1517/14728222.11.6.733
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???
AN - SCOPUS:34250158719
SN - 1472-8222
VL - 11
SP - 733
EP - 736
JO - Expert Opinion on Therapeutic Targets
JF - Expert Opinion on Therapeutic Targets
IS - 6
ER -